ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Cellectis (PK)

Cellectis (PK) (CMVLF)

3,47
0,00
( 0,00% )
Mis à jour : 20:31:03

Cellectis (PK) (CMVLF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
3,47
( - )
Prix Achat
2,67
Prix Vente
3,67
Volume échangé
-
0,00 Fourchette du Jour 0,00
2,58 Plage de 52 semaines 5,04
Cap du marché
Clôture Veille
3,47
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 301 736
Actions en circulation
72 601 869
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-4,34
Bénéfice par action (BPA)
-0,67
Chiffre d'affairess (LTM)
75,11M
Bénéfice net (LTM)
-67,23M

À propos de Cellectis (PK)

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is ... Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Siège social
Paris, France
Fondé
1999
Cellectis (PK) est coté dans le secteur Healthcare de la OTC Markets avec le ticker CMVLF. Le dernier cours de clôture d'Cellectis (PK) était de US$3,47. Au cours de la dernière année, les actions de Cellectis (PK) ont été négociées dans une fourchette de prix de US$ 2,58 à US$ 5,04.

Cellectis (PK) compte actuellement 72 601 869 actions en circulation. La capitalisation boursière d'Cellectis (PK) est de US$251,93 million. Cellectis (PK) a un ratio cours/bénéfice (ratio PE) de -4.34.

CMVLF Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
4003.473.473.4714003.47CS
120.3912.66233766233.083.473.083403.40117647CS
26-1.03-22.88888888894.54.53.081903.50631579CS
520.8934.4961240312.585.042.581823.83105691CS
1561.42569.68215158922.0455.040.952992.63205351CS
260-12.58-78.380062305316.0516.050.954434.65137009CS

CMVLF - Frequently Asked Questions (FAQ)

What is the current Cellectis (PK) share price?
The current share price of Cellectis (PK) is US$ 3,47
How many Cellectis (PK) shares are in issue?
Cellectis (PK) has 72 601 869 shares in issue
What is the market cap of Cellectis (PK)?
The market capitalisation of Cellectis (PK) is USD 251,93M
What is the 1 year trading range for Cellectis (PK) share price?
Cellectis (PK) has traded in the range of US$ 2,58 to US$ 5,04 during the past year
What is the PE ratio of Cellectis (PK)?
The price to earnings ratio of Cellectis (PK) is -4,34
What is the cash to sales ratio of Cellectis (PK)?
The cash to sales ratio of Cellectis (PK) is 2,81
What is the registered address of Cellectis (PK)?
The registered address for Cellectis (PK) is 8, rue de la Croix Jarry, Paris, Ile-de-France, 75013
What is the Cellectis (PK) website address?
The website address for Cellectis (PK) is www.cellectis.com
Which industry sector does Cellectis (PK) operate in?
Cellectis (PK) operates in the Biotechnology & Life Sciences sector

CMVLF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock